New agents for prostate cancer

To achieve more effective antitumor responses, it is clear that novel nonho rmonal therapeutics must be developed. Recent advances in the understanding of prostate cancer biology have led to the development of drugs directed a gainst precise molecular alterations in the prostate tumor cell. Biologic a gents now in development include those capable of altering signal transduct ion, blocking angiogenesis, inhibiting cell cycle progression, and stimulat ing apoptosis. Several new monoclonal antibodies are now being investigated . Evaluating these drugs and incorporating them into existing regimens are major goals of ongoing clinical research in advanced prostate cancer.